Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnership to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies for regenerative medicine products to support the advancement of cell and gene therapies.
On May 15, 2024, Richard Berman, Director of CryoPort Inc (NASDAQ:CYRX), executed a sale of 8,105 shares of the company, according to the SEC Filing.
Key Insights Cryoport to hold its Annual General Meeting on 17th of May Salary of US$865.6k is part of CEO Jerry...